Phase 1 Start
ANL: Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Anti
September 23, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 23, 2026
- Company
- Adlai Nortye Ltd. (ANL)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Anti
- Company
- Adlai Nortye Ltd. (ANL)
- Indication
- RAS Mutation; Solid Tumor (Phase I); CEACAM5